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Abstract 
Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL), 
and leukemia cell resistant to glucocorticoids confers a poor prognosis.  To elucidate 
mechanisms of glucocorticoid resistance, we determined the sensitivity to prednisolone of 
primary leukemia cells from 444 newly diagnosed ALL patients, revealing significantly higher 
expression of caspase 1 (CASP1) and its activator NLRP3 in glucocorticoid resistant leukemia 
cells, due to significantly lower somatic methylation of CASP1 and NLRP3 promoters.  Over-
expression of CASP1 resulted in cleavage of the glucocorticoid receptor, diminished 
glucocorticoid-induced transcriptional response and increased glucocorticoid resistance. 
Knockdown or inhibition of CASP1 significantly increased glucocorticoid receptor levels and 
mitigated glucocorticoid resistance in CASP1 overexpressing ALL.  Our findings establish a new 
mechanism by which the NLRP3/CASP1 inflammasome modulates cellular levels of the 
glucocorticoid receptor and diminishes cell sensitivity to glucocorticoids. The broad impact on 
glucocorticoid transcriptional response suggests this mechanism could also modify 
glucocorticoid effects in other diseases. 
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Glucocorticoids are steroid hormones that regulate multiple physiological processes involved in 
inflammation, immunity, metabolism and other homeostatic functions. They exert their effects 
by binding to the glucocorticoid receptor (GR, NR3C1), triggering its activation and 
translocation to the nucleus, leading to transcriptional changes responsible for diminished 
proliferative capacity and apoptosis of acute lymphoblastic leukemia (ALL) cells1. Synthetic 
glucocorticoids are widely prescribed medications used to treat a variety of human diseases with 
an inflammatory component (e.g., asthma and autoimmune disorders), and are an essential 
component of curative therapy of ALL and lymphomas.  Advances in the treatment of children 
with ALL have led to five-year disease-free survival rates exceeding 85%2. However, children 
whose ALL cells show in vitro resistance to glucocorticoids have a significantly worse treatment 
outcome (disease-free survival) than patients whose ALL cells are sensitive to glucocorticoids3–6. 
Yet, relatively little is known about the mechanisms causing leukemia cells from some patients 
to exhibit de novo resistance to glucocorticoids or why leukemia cells are more resistant to 
glucocorticoids at the time of disease recurrence5. 
 
Here we report higher expression of two pro-inflammatory genes, CASP1 and its activator 
NLRP3 (NLR family, pyrin domain containing 3) in primary ALL cells that exhibited de novo 
resistance to glucocorticoids.  We found that leukemia cells exhibiting higher expression of 
CASP1 and NLRP3 had significantly lower methylation of their promoter regions compared to 
glucocorticoid sensitive ALL.  We show that CASP1/NLRP3 overexpression induces 
glucocorticoid resistance via CASP1 cleavage of the glucocorticoid receptor in its transactivation 
domain, reducing cellular levels of functional glucocorticoid receptor and diminishing 
glucocorticoid transcriptional effects. We further show that enforced expression of a 
4 
 
glucocorticoid receptor that has been mutated to eliminate CASP1 cleavage sites mitigates 
glucocorticoid resistance due to CASP1 overexpression. Finally, we show that stably knocking 
down CASP1 expression with shRNA or reducing CASP1 activity with an inhibitory protein 
(CrmA) in CASP1-overexpressing leukemia cells increases cellular glucocorticoid receptor 
levels and markedly increases sensitivity to glucocorticoids.   
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Results 
Higher CASP1, NLRP3 in glucocorticoid resistant leukemia 
The de novo sensitivity of primary leukemia cells to prednisolone differed widely (>1000-fold) 
among patients in three independent cohorts of newly diagnosed children with ALL (Fig. 1A–C). 
We found that CASP1 and NLRP3, both members of the NALP3 inflammasome, were the two 
most highly over-expressed genes sharing a common pathway in steroid resistant ALL cells (Fig. 
1D–E, Supplementary Fig. 1). The mean expression of CASP1 in steroid resistant leukemia was 
1.6-fold higher than in sensitive leukemia cells (p = 3.2 × 10–7; Fig. 1D), whereas the mean 
expression of NLRP3 was 2.4-fold higher in prednisolone-resistant leukemia cells across all three 
cohorts of patients (p = 3.5 × 10–7; Fig. 1E). 
 
Methylation of CASP1 and NLRP3 regulates their expression 
To understand the basis for higher CASP1 and NLRP3 expression in glucocorticoid resistant 
leukemia cells, we assessed the relationship between CASP1 and NLRP3 mRNA expression and 
methylation of their promoter regions in leukemia cells. This revealed a highly significant 
relationship between the level of methylation of the CASP1 promoter and CASP1 mRNA 
expression in ALL cells (p = 1.4 × 10–22; Fig. 1F, Supplementary Fig. 2 panels A–C). In a subset 
of patients enrolled on St. Jude Protocol XVI where matching germline DNA from normal 
lymphocytes was available for methylation analysis (n = 55), CASP1 promoter methylation did 
not differ significantly (Paired t-test p = 0.495, Supplementary Fig. 3) in lymphocyte germline 
DNA and leukemia cell DNA across the entire population. In contrast, of 10 patients with 
significantly lower CASP1 promoter methylation in their ALL cells than their normal leukocytes, 
70% were glucocorticoid resistant (n = 7), consistent with somatic CASP1 demethylation in 
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glucocorticoid resistant ALL cells. Methylation of the promoter region of NLRP3 was 
significantly greater in leukemia cell DNA than in germline leukocyte DNA (Paired t-test p = 8.8 
x 10–11, Supplementary Fig. 3), and the level of NLRP3 promoter methylation in leukemia cells 
correlated significantly with NLRP3 expression in leukemia cells (p = 6.7 × 10–4; Fig. 1G, 
Supplementary Fig. 2 panels D–F). Categorization of patients using k-means clustering of 
NLRP3 methylation and CASP1 methylation levels significantly distinguished prednisolone-
sensitive (blue symbols) from prednisolone-resistant (orange symbols) leukemia cells (Fisher's 
Exact test for count data p = 4.7 × 10–7; Fig. 1H). 
 
CASP1 cleaves the glucocorticoid receptor 
Based on a prior report of CASP1 cleavage of the androgen receptor7, we identified a putative 
CASP1 cleavage site (LLID) in the transactivation domain of the glucocorticoid receptor (Fig. 
2A, upper panel), and we performed enzymatic assays that confirmed glucocorticoid receptor 
cleavage by recombinant CASP1 (Fig. 2A, lower panel). Site directed mutagenesis of the LLID 
motif ablated cleavage of the glucocorticoid receptor at this location (Fig. 2B) and led to the 
identification of a secondary CASP1 cleavage site (IKQE) (Fig. 2A, top). CASP1-induced 
cleavage of the glucocorticoid receptor was inhibited by both tetrapeptide (Fig. 2A, lower panel) 
and small molecule inhibitors (VX765 and VRT043198) of CASP18 (Fig. 2C). 
 
CASP1 over-expression increases glucocorticoid resistance 
We expressed full length CASP1 in a human leukemia cell line (NALM-6) to determine whether 
CASP1 over-expression increases resistance to glucocorticoids (Fig. 2D. Under standard 
conditions for activation of the NALP3 inflammasome and CASP19–13, cells transduced with 
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empty vector control virus did not show differences in their sensitivity to prednisolone or 
dexamethasone, whereas cells transduced with CASP1-expressing virus had markedly higher 
LC50 for prednisolone and dexamethasone (Fig. 2E).  On average, CASP1 over-expression 
increased resistance to prednisolone by 16.9-fold (Student's t-test p = 5.7×10–6) and 
dexamethasone by 5.3-fold (Student's t-test p = 1.2×10–9), with a 35% reduction in 
glucocorticoid receptor levels by 24 hours (Fig 2E).  This was validated in a different human 
ALL cell line (697), revealing a similar increase in resistance to glucocorticoids (Supplementary 
Fig. 4).  
 
CASP1 blunts transcriptional response to glucocorticoids 
Because glucocorticoids regulate expression of target genes by binding to the glucocorticoid 
receptor, triggering its translocation into the nucleus and association with a glucocorticoid 
response element (GRE) to increase or decrease gene transcription, we assessed the ability of 
glucocorticoids to influence global gene expression in the presence or absence of CASP1 
enforced expression. This revealed markedly diminished glucocorticoid-induced changes in gene 
expression levels in cells with CASP1 enforced expression compared to controls (Fig. 3A, 3B).  
Likewise, induction of Bim protein levels, encoded by BCL2L11, a known glucocorticoid 
response gene, was markedly blunted in CASP1 overexpressing cells (Fig. 3A inset). BCL2L11 
upregulation was also significantly blunted at the mRNA level in CASP1 overexpressing cells as 
compared to control (fold change = 1.39 ± 0.12 versus fold change = 1.78 ± 0.17, p = 0.024).  
Genome wide assessment of changes in gene expression after glucocorticoid treatment (results of 
4 replicate experiments) identified 93 genes that were induced by at least 3-fold following 
glucocorticoid treatment of control cells, 64 (68%) of which had lower (by at least 25%) 
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induction in CASP1 overexpressing cells.  Among these genes, the mean induction in control 
cells was 8.4-fold, compared to only 4.4-fold in CASP1 overexpressing cells (Paired t-test p = 
0.01).  Analysis of the sequences of these genes (including 5 kilobases up and downstream of 
each), showed a significant enrichment (46/93, 49%) of either known GREs (glucocorticoid 
receptor binding motif, Supplementary Table 1, motifs 1–9,14–16) or a genomic region shown by 
ChIP-seq experiments to bind the glucocorticoid receptor14, as compared to only 28% 
(1409/5000) of the randomly selected unchanged genes (Fisher’s Exact Test p = 2.2 × 10–5). 
Inclusion of an additional motif containing the top two most frequent bases at each position of a 
previously reported motif16 (motif 10, Supplementary Table 1) increased the percentage of 
upregulated genes with a GRE to 62% (58/93) of the transactivated genes. 
Of the 119 genes whose expression was down-regulated by at least 50% following 
glucocorticoid treatment of control cells, 98 (82%) of these 119 genes were down-regulated to a 
lesser extent (by at least 25%) in CASP1 overexpressing cells.  Among these genes, the mean 
reduction in control cells was 58%, compared to only 33% in CASP1 overexpressing cells 
(Paired t-test p < 2.2 × 10–16).  Analysis of the sequences of these genes, including 5 kilobases up 
and downstream, revealed a significant enrichment (29/119, 24%) of NF-κB binding motifs (a 
transcription factor known to interact with an activated glucocorticoid receptor, Supplementary 
Table 1, motif 11) or a genomic region shown by ChIP-seq to bind to the glucocorticoid 
receptor14, as compared to randomly selected unchanged genes (849/5000, 17%; Fisher’s Exact 
Test p = 0.048).  The top 50 up-regulated and down-regulated genes in control cells and their 
changes in cells with CASP1 enforced expression are depicted in Fig. 3, with the complete gene 
lists provided in the supplement (Supplementary Tables 2–4). 
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Additionally, CASP1 expression blunted genome-wide glucocorticoid receptor binding to DNA 
in response to prednisolone, as evidenced by ChIP-seq.  The distribution of normalized read 
count ratios at all reproducible glucocorticoid receptor binding sites identified across control and 
CASP1 overexpressing cells showed a more than 4 fold enrichment of reads in control cells and 
96% of all glucocorticoid receptor binding events displayed stronger read enrichments in control 
cells (Fig. 3C), in line with a lower level of functional glucocorticoid receptor from CASP1 over-
expression.  In support of these analyses, an assessment of identified binding sites revealed a 
marked overlap in glucocorticoid receptor binding events (Fig. 3E) between control and CASP1 
overexpressing cells, and a 2.9 fold enrichment in the total number of binding sites was observed 
in control cells (10024 versus 3467 sites in control and CASP1 overexpressing cells, 
respectively).  Notably, the top DNA-binding motif identified for control and CASP1 
overexpressing cells (Fig. 3D) is consistent with the canonical glucocorticoid receptor binding 
motif.  The extent of ChIP enrichment in control cells compared to CASP1 overexpressing cells 
is exemplified for four genes in Fig. 3F. Glucocorticoid receptor binding in CASP1 
overexpressing cells consistently exhibit less ChIP enrichment compared to glucocorticoid 
receptor binding in control cells.  Collectively, these data document a lower level of genome-
wide glucocorticoid receptor occupancy in CASP1 overexpressing cells.  
 
CASP1 and NLRP3 expression is higher in relapsed leukemia 
To determine whether CASP1 and NLRP3 expression differed in leukemia cells at the time of 
disease recurrence (Fig. 4), we examined the mRNA expression levels of CASP1 and NLRP3 in 
paired ALL cells obtained at diagnosis and relapse from forty-nine patients17. This showed 
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significantly higher expression of both CASP1 and NLRP3 in ALL cells at the time of relapse 
when compared to the corresponding samples obtained from the same patients at diagnosis 
(Paired t-test p = 3.2 × 10–4 and 4.2 × 10–3 respectively). Likewise, in a separate cohort of 
patients, we found that ALL cells at the time of disease recurrence (relapse) were more resistant 
to glucocorticoids when compared to sensitivity at the time of initial diagnosis (Fig. 4C; p = 9.72 
× 10–7). 
 
CASP1 inhibition reverses glucocorticoid resistance 
To determine whether inhibition of CASP1 could diminish CASP1-induced glucocorticoid 
receptor cleavage and increase sensitivity to glucocorticoid treatment, we first used shRNA to 
knockdown over-expressed CASP1. This revealed that knockdown of CASP1 expression by 
~50% (Fig. 5A, shCASP1) reduced CASP1-induced glucocorticoid receptor cleavage (Fig. 5A, 
shCASP1), and markedly enhanced glucocorticoid sensitivity (prednisolone LC50 = 12.8 ± 4.7 
µM vs. 570 ± 423.2 µM, mean ± S.E.M., 44-fold reduction, t-test p = 0.028) (Fig. 5C, shCASP1) 
in CASP1 overexpressing ALL cells when compared to cells transduced with scrambled non-
targeting shRNA (Fig. 5C, shNT).  
 
Likewise when we transduced CASP1 overexpressing NALM-6 cells with the gene encoding 
CrmA (cytokine response modifier A),  a known inhibitor of CASP1 catalytic activity18–20, this 
blocked CASP1 induced glucocorticoid receptor cleavage (Fig. 5B) and markedly increased 
sensitivity to glucocorticoids (3.2 ± 0.2 µM vs. 137.3 ± 24.3 µM, mean ± S.E.M., 43-fold 
reduction in LC50, t-test p = 0.011, Fig. 5D) when compared to GFP transfected controls.  
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We also over-expressed CrmA + RFP or RFP alone in glucocorticoid resistant primary leukemia 
cells that had a high level of CASP1 expression compared to several other glucocorticoid 
sensitive primary leukemia xenografts (not shown). This led to a diminution of the de novo 
glucocorticoid resistance (Supplementary Fig. 6A, dexamethasone LC50 = 0.14 μM (95% 
confidence interval = 0.1426 × 10–2 – 0.2773 μM  versus > 10 μM, p < 1 × 10–14) and partial 
restoration of glucocorticoid receptor protein levels (Supplementary Fig. 6B).  The levels of 
CASP1 expression in glucocorticoid-resistant primary ALL cells isolated from two patients 
(prednisolone LC50 = 1387 µM and 206.4 µM) were comparable to that of the glucocorticoid-
resistant NALM-6 ALL cells in which heterologous CASP1 was over-expressed to recapitulate 
this mechanism of  glucocorticoid-resistance (Supplementary Fig. 7). 
 
Removal of CASP1 cleavage sites mitigates resistance 
We overexpressed full length wild-type glucocorticoid receptor or a glucocorticoid receptor that 
had been mutated to eliminate the CASP1 cleavage sites (i.e., alanines substituted for the LLID 
and IKQE motifs identified in in vitro enzymatic assays), in leukemia cells overexpressing 
CASP1 in combination with either shRNA-based knockdown of overexpressed CASP1 or non-
targeting shRNA control. Enforced expression of wild-type glucocorticoid receptor was unable 
to reverse CASP1 induced glucocorticoid resistance, whereas expression of a glucocorticoid 
receptor without the CASP1 cleavage sites markedly attenuated CASP1 induced glucocorticoid 
resistance (9.4-fold reduction in LC50), restoring sensitivity to levels similar to cells with 
shRNA-based knockdown of overexpressed CASP1 (Fig. 6). 
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Discussion 
The present study has revealed a novel mechanism by which CASP1 and its activator NLRP3 
modulate the biological and pharmacological effects of glucocorticoids via cleavage of the 
glucocorticoid receptor. Glucocorticoids mediate their effects by binding to the glucocorticoid 
receptor, causing it to translocate into the nucleus where it modulates the expression of genes 
that contain a GRE. Prior work has shown that low cellular levels of functional glucocorticoid 
receptor, due either to siRNA knockdown14,21, rare mutations in the human NR3C1 gene 
encoding the glucocorticoid receptor22 or heterogeneity in the cellular levels of glucocorticoid 
receptor in leukemia cells by undefined mechanisms23, decrease sensitivity to glucocorticoids. 
However, it was previously not known that CASP1 can cleave the glucocorticoid receptor and 
thereby reduce functional receptor levels and modulate cellular response to glucocorticoids.  
 
We have demonstrated that recombinant CASP1 cleaves the glucocorticoid receptor in its 
transactivation domain, and that forced over-expression of CASP1 coupled with its activation via 
the NLRP3 inflammasome causes human leukemia cells to become more resistant to 
glucocorticoids. Overexpression of CASP1 without its activation via the NLRP3 inflammasome 
did not alter glucocorticoid sensitivity of leukemia cells, demonstrating that catalytically active 
CASP1 is required for loss of glucocorticoid sensitivity. Further, overexpression of a 
glucocorticoid receptor lacking CASP1 cleavage sites mitigated the effects of CASP1 
overexpression on leukemia cell sensitivity to glucocorticoids. Activation of the NALP3 
inflammasome in the absence of CASP1 overexpression had only a small effect on 
glucocorticoid resistance, possibly due to activation of endogenous CASP1. Furthermore, our 
finding of higher expression of CASP1 and NLRP3 in leukemia cells at the time of disease 
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relapse provides a plausible mechanism for prior observations that leukemia cells at relapse are 
more resistant to prednisolone compared to leukemia cells at initial diagnosis19. In support of 
this, we observed markedly greater resistance to dexamethasone in ALL cells obtained from 
patients at the time of relapse. Likewise, using publically available data, we found that many 
glucocorticoid-resistant ALL cell lines24,25 and primary ALL xenografts26,27 express relatively 
high levels of CASP1 (supplemental Figure 8). Collectively, this indicates that although there are 
multiple mechanisms via which ALL cells can become resistant to glucocorticoids28–30, CASP1 
over-expression in glucocorticoid resistant ALL is not uncommon. 
 
Importantly, when we knocked down CASP1 expression in CASP1 overexpressing cells, we 
were able to reverse CASP1-induced glucocorticoid receptor cleavage and markedly increase 
sensitivity to glucocorticoids, suggesting CASP1 inhibition as a potential new therapeutic 
strategy to mitigate glucocorticoid resistance. There have been small molecule CASP1 inhibitors 
in clinical development31, although phase 2 clinical trials for epilepsy failed to show therapeutic 
benefit and were terminated31. The lack of clinical efficacy of this class of agents is consistent 
with their inability to reverse glucocorticoid resistance in our CASP1 overexpressing cells, 
which may be due to their poor penetration into cells (not shown). Our experiments showing that 
CrmA inhibition of CASP1 catalytic activity restores sensitivity to glucocorticoids in CASP1 
overexpressing leukemia cells provide a proof of principle for this strategy and a strong rationale 
for future studies to identify small molecule CASP1 inhibitors that can achieve sufficient cellular 
concentrations to reverse glucocorticoid resistance in CASP1 overexpressing leukemia cells. 
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CASP1 belongs to a family of cysteine proteases that cleave proteins following an aspartic acid 
residue. Produced as a pro-enzyme, CASP1 requires removal of its caspase activation and 
recruitment domain (CARD) before it becomes an active enzyme32.  CARD cleavage is mediated 
by the formation of inflammasomes, of which the most extensively characterized is the NALP3 
inflammasome. NALP3 (encoded by NLRP3) can be activated by exposure to pathogen 
associated molecular pattern or damage associated molecular pattern molecules, or by whole 
pathogens or environmental irritants32. There is also emerging evidence that the NALP3 
inflammasome can form in response to host-derived molecules, including extracellular ATP, 
glucose or monosodium urate crystals10,32–34. In vivo induction of the NALP3 inflammasome 
typically results in self-oligomerization, recruitment of the ASC (PYCARD) adaptor protein, and 
clustering and auto-activation of CASP1. CASP1 is known to have pro-inflammatory effects, 
including the activation of inflammatory cytokines (e.g. interleukin 1β and interleukin 18). Our 
findings raise the possibility that during inflammatory processes, CASP1 negatively regulates 
anti-inflammatory glucocorticoid signaling to further amplify the pro-inflammatory effects of the 
NALP3 inflammasome. 
 
The significant effects we observed on glucocorticoid sensitivity by partial reduction of cellular 
glucocorticoid receptor levels is consistent with prior studies showing that glucocorticoid 
receptor (NR3C1) haploinsufficiency produces a number of phenotypes including familial 
glucocorticoid resistance35 and adrenal hyperplasia36, alters blood pressure, glucose and lipid 
homeostasis in glucocorticoid receptor heterozygous mice37 and causes glucocorticoid resistance 
in Jurkat leukemia cells38. 
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The fact that not all glucocorticoid responsive genes were affected by CASP1 overexpression 
likely reflects differences among genes in their sensitivity to activated glucocorticoid receptor as 
a transcription factor. Whether glucocorticoids cause transactivation or transrepression of a given 
gene is determined in part by the presence or absence of either a positive GRE, leading to 
transactivation or a negative GRE leading to transrepression. Glucocorticoids may also repress 
gene expression via binding of the activated glucocorticoid receptor to transcription factors such 
as NF-κB and AP139,40. Although we found a significant enrichment of positive GREs among 
transactivated genes and negative GREs in transrepressed genes, failure to find GREs in all 
glucocorticoid-responsive genes likely reflects the current incomplete definition of GREs. Our 
ChIP-seq experiments showed that DNA binding by the glucocorticoid receptor is markedly 
diminished in CASP1 overexpressing cells.  The broad spectrum of genes affected in CASP1 
overexpressing cells indicates that our findings likely have broader implications, beyond the 
modulation of the anti-leukemic effects of glucocorticoids.  
 
Taken together, our findings demonstrate a novel mechanism whereby leukemia cells develop 
resistance to glucocorticoids via somatic epigenetic changes that cause overexpression of CASP1 
and NLRP3, leading to enhanced CASP1-mediated cleavage of the glucocorticoid receptor and 
diminished cellular response to glucocorticoids. These findings provide the foundation for future 
efforts to identify small molecule inhibitors of CASP1 that can reverse this mechanism of 
glucocorticoid resistance and thereby improve the treatment of acute lymphoblastic leukemia and 
potentially other illnesses for which glucocorticoids are used therapeutically. 
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expression data available at GEO accession: GSM852997. 
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Figure Legends  
Figure 1 
Glucocorticoid resistant leukemia cells have higher expression and hypo-methylation of 
CASP1 and NLRP3 genes 
Primary leukemia cells were obtained from 444 patients (B and T cell leukemia) with newly 
diagnosed acute lymphoblastic leukemia and analyzed for their sensitivity to prednisolone using 
the MTT assay (see Methods)28. Distributions of measured LC50 values are shown for the three 
independent cohorts of patients; sensitive and resistant leukemias are highlighted in blue and 
orange, respectively (panels A–C). CASP1 (panel D) and NLRP3 (panel E) expression was 
significantly higher in glucocorticoid resistant leukemia cells from these three cohorts of newly 
diagnosed patients with B-lineage leukemia. In both patient cohorts for whom DNA was 
available for DNA methylation analysis (St. Jude Protocols XV and XVI), significantly lower 
levels of CASP1 (panel F) and NLRP3 (panel G) methylation were found in leukemia cells (from 
patients with B lineage leukemia) with higher expression of CASP1 and NLRP3. k-means 
clustering analysis (▲ represents k-means identified group A, ● represents k-means identified 
group B, pink and red squares represent k-means identified centers for group A and B 
respectively) utilizing only CASP1 and NLRP3 methylation status significantly discriminated 
sensitive leukemias (blue symbols, higher methylation) from resistant leukemias (orange 
symbols, lower methylation) in both St. Jude Protocol XV and XVI (panel H and supplementary 
Fig. 2) patients.  Welch’s t-test p-values are shown for panels 1D–G and Fisher's Exact test p-
value is shown for panel H. Boxes and whiskers are as defined in Online Methods. 
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Figure 2 
CASP1 cleaves the glucocorticoid receptor and increases resistance to glucocorticoids 
Bioinformatic analysis of the glucocorticoid receptor amino acid sequence (panel A, top) 
revealed a putative CASP1 cleavage site (LLID) in the glucocorticoid receptor (NR3C1) 
transactivation domain that is similar to a previously reported CASP1 cleavage site in the 
androgen receptor. Enzymatic assays revealed that recombinant CASP1 cleaves the 
glucocorticoid receptor and that this cleavage was inhibited by a CASP1 tetrapeptide inhibitor 
(panel A, bottom).  Site directed mutagenesis of NR3C1 at the putative cleavage site (LLID 
motif) blocked CASP1 cleavage at this location and revealed a secondary CASP1 cleavage site 
more proximal to the carboxy terminus of the protein, as evidenced by a smaller enzymatic 
product (panel B). Further inhibition studies showed that small molecule inhibitors VX-765 and 
VRT-043198 (panel C) can also inhibit recombinant CASP1 cleavage of NR3C1, with VRT-
043198 having higher inhibitory activity. Enforced expression of CASP1 in a human leukemia 
cell line (NALM-6) increased resistance to prednisolone and dexamethasone after activation of 
the NALP3 inflammasome (by the addition of LPS and ATP). NALM-6 cells were transduced 
with a lentivirus containing full length CASP1 and puromycin N-acetyl-transferase or 
puromycin N-acetyl-transferase alone (Control). Cells were puromycin selected and then their 
sensitivity to prednisolone and dexamethasone (panel E, data is representative of four 
independent experiments with standard deviation error bars) was measured using the MTT assay, 
in the presence(+) and absence(-) of inflammasome activation (LPS/ATP). The panel E inset is a 
western blot depicting the lower glucocorticoid receptor protein levels in cells over expressing 
CASP1 (24 hours after activation of CASP1). 
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Figure 3 
Transcriptional modulation induced by glucocorticoids is diminished by CASP1 
Genome-wide gene expression was measured (n = 4) with median values shown (panels A and 
B, error bars depict median absolute deviation) and fold-differences (with or without 
prednisolone treatment) were compared between control cells treated with prednisolone and the 
same cells not treated with prednisolone or in cells with enforced expression and activation of 
CASP1 treated with prednisolone or not. The top 50 genes activated (blue bars) and repressed 
(green bars) by prednisolone in untreated control cells are shown, with the fold-change in CASP1 
overexpressing cells shown by the adjacent gold bars. Additionally, control and CASP1 
overexpressing cells were treated with and without prednisolone and LPS/ATP and protein 
lysates were collected for determination of Bim protein levels by western blotting, a known 
glucocorticoid response gene (panel A inset).  The histogram (panel C) depicts the distribution of 
average normalized read count ratios at all reproducible glucocorticoid receptor binding sites 
identified across control and CASP1 overexpressing cells after prednisolone treatment.  Binding 
sites with values above 0 highlight stronger enrichment in control cells while ratio values less 
than 0 depict sites with stronger enrichment in CASP1 overexpressing cells. The top binding 
motif identified (Panel D) is consistent with the canonical glucocorticoid receptor motif in both 
control and CASP1 overexpressing cells.  The number and the extent of overlap of 
glucocorticoid receptor binding sites found is given in Panel E.  ChIP enrichments near 
prednisolone-responsive genes are shown for 4 genes in Panel F.  The images display ChIP 
enrichment in control cells (upper) and CASP1 overexpressing cells (lower).   
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Figure 4 
CASP1 and NLRP3 expression is higher and glucocorticoid resistance is greater in 
leukemia cells at the time of disease relapse 
Expression levels of CASP1 (panel A) and NLRP3 (panel B) in leukemia cells obtained from 49 
patients at diagnosis and at the time of disease relapse. Quantile normalized measures of gene 
expression revealed significantly higher expression of NLRP3 and CASP1 at relapse. Paired t-test 
values are shown for panels A and B.  Panel C depicts dexamethasone sensitivity (LC50) for 7 
paired leukemia (ALL) cells obtained at diagnosis and at relapse from the same patients 
(connecting lines).  Boxes and whiskers are as defined in Online Methods. 
 
Figure 5 
Knockdown or inhibition of CASP1 reverses glucocorticoid receptor cleavage and 
prednisolone resistance 
NALM-6 cells overexpressing CASP1 were transduced with lentiviral vectors containing non-
targeting scrambled hairpin (shNT) or shRNA hairpins targeting CASP1 (shCASP1). The two 
cell lines were cultured for 48 hours in the presence and absence of LPS/ATP, and analyzed on 
Western blot for the levels of CASP1 and glucocorticoid receptor (Panel A). The intensities of 
the glucocorticoid receptor and active CASP1 normalized against HSP90, are shown in Panel A. 
After activation of CASP1 (Panel A, lane 2 and 4), glucocorticoid receptor is approximately 2-
fold lower in scrambled hairpin cells (Panel A, lane 4) whereas shCASP1 cells showed minimal 
degradation of the glucocorticoid receptor  (Panel A, lane 2).  
The prednisolone sensitivity (LC50) of shCASP1 and shNT cells was determined by MTT assays 
(Panel C). In the absence of CASP1 activation (– LPS/ATP), the PRED-LC50 of shCASP1 and 
shNT cells were comparable (Panel B). Upon activation of CASP1, shCASP1 cells were 44-fold 
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more sensitive to prednisolone compared to shNT cells (Panel C). Error bars represent S.E.M, n 
= 4.  Transduction of CrmA in CASP1 overexpressing cells showed effects similar to knockdown 
of CASP1 by shRNA. Without CASP1 activation, the PRED-LC50 for CrmA-expressing cells 
and GFP-expressing cells was comparable (Panel D). However, upon activation of CASP1, 
CrmA blocked CASP1 induced glucocorticoid receptor cleavage (Panel B) and increased 
glucocorticoid sensitivity by 43-fold compared to the GFP expressing control cells (Panel D).  
Error bars are as defined for Panel C. 
 
Figure 6 
Expression of glucocorticoid receptor with both CASP1 cleavage sites mutated to AAAA 
mitigates CASP1 induced prednisolone resistance 
NALM-6 cells overexpressing CASP1 co-transfected with either non-targeting scrambled hairpin 
(shNT) or shRNA hairpins targeting CASP1 (shCASP1) were stably transduced with lentiviral 
vectors containing a wild-type glucocorticoid receptor or a glucocorticoid receptor in which both 
CASP1 cleavage sites had been eliminated  (double mutagenized glucocorticoid receptor, DM-
GR). The sensitivity (LC50) of these cells to prednisolone was determined by MTT assays, 
revealing that cells overexpressing a glucocorticoid receptor without CASP1 cleavage sites 
remained sensitive to glucocorticoids when CASP1 was over-expressed. The inset is a western 
blot depicting recombinant glucocorticoid receptor protein levels (wild-type, or double 
mutagenized), in cells at time of MTT drug sensitivity assays.  Data are representative of three 
independent experiments with standard deviation bars. 
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Online Methods 
Patients 
A total of 444 children aged 18 years or younger with newly diagnosed ALL were included in 
this study. Two hundred seventy one were enrolled on the St. Jude Total Therapy XV or XVI 
protocols; 173 were enrolled on the 9th ALL Dutch Childhood Oncology Group protocol at 
Erasmus Medical Center, Sophia Children's Hospital, in Rotterdam, The Netherlands or on 
treatment protocols 92 and 97 of the German Cooperative Study Group for Childhood Acute 
Lymphoblastic Leukemia in Hamburg, Germany.  Patients were enrolled in these studies if they 
had a diagnosis of ALL, were younger than 18 years of age, and had not been previously treated 
for ALL.  In an additional cohort of 49 pediatric patients with relapsed B-precursor ALL, 
cryopreserved bone marrow samples from diagnosis and relapse from the Children's Oncology 
Group (COG) were subjected to gene expression analysis as previously described.17 All patients 
in the relapsed cohort had a bone marrow or bone marrow/central nervous system combined 
relapse and had been initially treated on COG protocols for newly diagnosed ALL17. In a 
separate cohort of patients enrolled at St. Jude Children’s Research Hospital, dexamethasone 
LC50 was measured at time of diagnosis and relapse.  Written informed consent was obtained 
from all patients or their parents/guardians, and assent from the patients, as appropriate. The 
research and use of these samples were approved by the institutional review board at the host 
institution.  
 
Gene expression analyses 
Total RNA was extracted with TriReagent (Molecular Research Center, Inc.) from freshly 
isolated or cryopreserved mononuclear cell suspensions from patient bone marrow aspirates 
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obtained at diagnosis. In the COG relapsed cohort, an RNA sample was extracted from leukemia 
cells from patient bone marrow aspirates obtained at the time of original diagnosis and again at 
the time of disease recurrence. All gene expression microarrays were performed by the St. Jude 
Children’s Research Hospital, Hartwell Center for Bioinformatics & Biotechnology. High-
quality RNA was hybridized to the HG-U133A (GPL96) or HG-U133 Plus 2.0 (GPL570) 
oligonucleotide microarrays in accordance with the manufacturer’s protocol (Affymetrix). These 
microarrays contain 22,283 or 54,675 gene probe sets, representing approximately 18,400 or 
47,400 human transcripts, respectively. Gene expression data were MAS5 41 processed using the 
affy42 Bioconductor43 R-project package or using Affymetrix Microarray Suite version 5.044,45 as 
previously described28. 
 
DNA methylation analyses 
DNA was isolated at the time of diagnosis from leukemia cells obtained from patients via bone 
marrow aspirates. Genome-wide DNA methylation status was determined using either an 
Infinium HumanMethylation27 BeadChip Kit or Infinium HumanMethylation450 BeadChip Kit 
in accordance with the manufacturer’s protocol (Illumina). HumanMethylation27 BeadChip 
experiments were performed at either Emory Integrated Genomics Core (EIGC) or Wellcome 
Trust Centre for Human Genetics Genomics Lab, Oxford, UK. HumanMethylation450 BeadChip 
experiments were performed at the Heflin Center for Genomic Science at the University of 
Alabama at Birmingham. DNA methylation status was classified as low if the Beta value46 was 
less than or equal to 0.25 and high if greater than 0.25. 
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Statistical analyses 
Analyses were performed using R software unless otherwise specified. Exact Wilcoxon Mann-
Whitney Rank Sum tests were used for analyses of differential gene expression and differential 
DNA methylation and Stouffer’s Z-score method was used for meta-analysis47. For boxplots, 
the upper and lower value of each box depicts the 75th and 25th percentile respectively, the solid 
line depicts the group median and the top and bottom of each dashed vertical line depicts the 
most extreme data point which is no more than 1.5 times the interquartile range (75th percentile 
– 25th percentile) from the box. K-means clustering analysis with a k = 2 was used for DNA 
methylation data and either untransformed or log-transformed gene expression data, with 
Fisher’s exact test for determining clustering significance. Fisher’s exact test was used to assess 
the significance of enrichment of known GREs.   
 
CASP1 enzymatic assays 
Recombinant human CASP1 (100–200 U, where U = 1 pmol/min at 30°C, 200 μM YVAD-pNA) 
from a CASP1 assay kit for drug discovery (Enzo Life Sciences, catalog number BML-AK701-
0001) was incubated at 30°C with wild-type or mutated glucocorticoid receptor in the presence 
(10 µM unless otherwise indicated) or absence of inhibitors, (Ac-YVAD-CHO, Enzo Life 
Sciences, catalog number BML-P403-9090), VX765, VRT-043198. Substrates for enzyme 
assays were prepared in CASP1 assay buffer (Enzo Life Sciences, catalog number KI-111) 
consisting of 50 mM HEPES, pH7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM DTT, 1 mM EDTA 
and 10% glycerol. 
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Site-directed mutagenesis 
Site-directed mutagenesis was performed on NR3C1 using a QuikChange Site-Directed 
Mutagenesis Kit (Stratagene). Mutagenesis of the LLID motif was performed in 4 sequential 
mutagenesis reactions from Myc-DDK tagged NR3C1 (Origene, Rockville, MD, catalog # 
RC220189). The following mutagenesis primers were used: MutF1-4-NR3C1 and MutR1-4-
NR3C1 (supplemental table 5). Mutagenesis of the IKQE motif was performed in 2 sequential 
mutagenesis reactions from the LLID mutated NR3C1.  The following mutagenesis primers were 
used: MutF5-6-NR3C1 and MutR5-6-NR3C1 (supplemental table 5). 
Successful mutagenesis was confirmed by Sanger sequencing. 
 
Sensitivity of leukemia cells to glucocorticoids 
Leukemia cells were isolated at diagnosis from patient bone marrow aspirates. If the leukemia 
cell percentage from diagnostic bone marrow samples was less than ninety percent, magnetic 
activated cell sorting (Miltenyl Biotec) was performed to further enrich leukemia cells. If red cell 
contamination was greater than thirty percent, red blood cell lysis was performed. Cells were 
centrifuged at 300g for five minutes and resuspended in RPMI-1640 with 2 mM L-glutamine, 
20% heat-inactivated fetal bovine serum, 1X Antibiotic-Antimycotic solution (Life 
Technologies) and 1X ITS solution (Life Technologies) at a concentration of two million cells 
per milliliter. Eighty microliters of this leukemia cell suspension was then plated into each 
experimental well of round-bottom 96-well plates. Twenty microliters of decreasing 
concentrations of prednisolone were added and the plates were incubated for ninety-six hours in 
a humidified incubator containing 5% CO2 at 37°C. For the final six hours, ten microliters of 5 
milligram per milliliter MTT (3-4,5-dimethylthiazol-2,5-diphenyl tetrazolium bromide) was 
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added to each experimental well. Drug resistance assays in NALM-6 and 697 cell lines (Leibniz-
Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) were 
performed using between 0.25 and 2.5 million cells per milliliter. Assays were developed and 
performed as described for primary ALL cells. LC50 values were determined for patients at 
diagnosis or replapse as previously described28, and consistent with prior analyses, 
glucocorticoid resistant ALL was defined as having an LC50 of 64 µM or greater, whereas 
glucocorticoid sensitive cases were defined as having an LC50 less than 0.1 µM.  Among patients 
treated on the Total XV protocol (the only uniformly treated cohort with sufficient follow-up to 
assess event free survival), those patients whose samples were classified as sensitive to 
prednisolone (LC50 < 0.1 µM) had a significantly better treatment outcome than the other 
patients, (5 year event free survival 95.6% vs. 82.7%, p = 0.01 logrank test). 
 
CASP1 enforced expression 
Full length CASP1 cDNA (Origene, catalog # RC218364) was subcloned into a lentiviral 
backbone (System Biosciences, catalog number CD527A-1), in frame with a T2A linked 
puromycin resistance gene.  Lentivirus was produced in 293T cells and the NALM-6 leukemia 
cell line was transduced. Seventy-two hours post transduction, cells were selected with 2.5 
micrograms per milliliter puromycin. Where indicated, cells were treated with 10 µg/mL LPS 
(InvivoGen) followed 2 hours later by 5 mM ATP (Roche). NALM-6 and 697 cell lines were 
routinely authenticated and screened for mycoplasma.  
 
Expression of mutant glucocorticoid receptor without CASP1 cleavage sites 
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Doubly mutated NR3C1 (LLID and IKQE) was subcloned into the pLX30448 lentiviral backbone 
(Addgene plasmid 25890). Lentivirus was produced in 293T cells and NALM-6 leukemia cell 
lines with CASP1 overexpression and shRNA directed towards CASP1 or a non-targeting shRNA 
were transduced. Seventy-two hours post transduction, cells were selected with blasticidin.   
 
Expression of GFP and CrmA 
Green fluorescent protein (Addgene plasmid 15301)49 or CrmA encoding cDNAs (Addgene 
plasmid 11832)50 was subcloned into the pLX30448 lentiviral backbone (Addgene plasmid 
25890). Lentivirus was produced in 293T cells and NALM-6 leukemia cell lines with CASP1 
overexpression and shRNA directed towards CASP1 or a non-targeting shRNA were transduced. 
Seventy-two hours post transduction, cells were selected with blasticidin.   
 
Western blotting 
In brief, cells were pelleted by centrifugation, washed once with PBS and lysed with RIPA 
buffer or CASP1 assay buffer (Enzo Life Sciences, catalog number KI-111), equal amounts of 
proteins (1–20 µg) separated by 4–12% Novex Bis-Tris gels (Life Technologies), and then 
transblotted to PVDF membranes (Life Technologies). Anti-glucocorticoid receptor (1:1000–
1:10,000, BD catalog number 611227), anti-CASP1 p20 (Adipogen catalog number AG-20B-
0048), anti-DDK tubulin (1:1000, Origene catalog number TA50011), anti-Bim (1:1000, Cell 
Signaling catalog number 2819) anti-Tubulin (1:1000, Santa Cruz, sc-8035), or anti-HSP90 
(1:1000, Cell Signaling catalog number 4874) were used as primary antibodies followed by 
appropriate secondary HRP-conjugated IgG (1:1000, Dako) and immunocomplexes were 
visualized by chemiluminescence using a Chemidoc Imager (BioRad). Signal intensities of 
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CASP1 and glucocorticoid receptor where quantified using Quantity One Software (BioRad) and 
normalized for the signal intensity of the loading control in the same lane.  
 
Glucocorticoid induced changes in gene expression 
NALM-6 transduced with either empty vector (control) or CASP1 containing lentiviral particles 
were treated with or without LPS/ATP, with or without 0.3 mM prednisolone, for 24 hours. RNA 
was extracted and hybridized to Affymetrix PrimeView oligonucleotide microarrays and RMA 
processed.  
To be included as a gene that was transactivated by glucocorticoids, the median level of mRNA 
expression from 4 replicate experiments had to increase in control cells by at least 3-fold. To be 
included as a gene that was transrepressed by glucocorticoids, the median level of mRNA 
expression had to decrease by at least 50%. 
 
Chromatin immunoprecipitation sequencing 
NALM-6 transduced with either empty vector (control) or CASP1 containing lentiviral particles 
were treated with or without LPS/ATP, and with or without 0.3 mM prednisolone for 24 hours. 
Chromatin immunoprecipation sequencing (ChIP-seq) was performed with an antibody to the 
glucocorticoid receptor (Santa Cruz sc-1003), as previously described51.  Briefly, cells were 
cross-linked with formaldehyde (1% final concentration) for 10 minutes at room temperature and 
then incubated with glycine (0.125 M final concentration) for 5 minutes to stop the cross-linking 
reaction.  Cells were pelleted and washed with 1X PBS containing protease inhibitors (Roche 
Protease Inhibitor Cocktail Tablets, 11836153001) and stored at –80C prior to further 
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experimentation.  Crosslinked cell pellets were resuspended in cold lysis buffer (5 mM PIPES 
pH 8.0, 85 mM KCl and 0.5% NP-40 solution) containing protease inhibitors (Roche Protease 
Inhibitor Cocktail Tablets, 11836153001), and pelleted to isolate nuclei.  The pellet was 
resuspended in cold RIPA lysis buffer (1X PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS solution).  Sonication was performed using a Bioruptor sonication system (Diagenode).  
Sonicated chromatin was added to Dynabeads (Invitrogen) coated with anti-glucocorticoid 
receptor antibodies (sc-1003) and incubated overnight at 4°C.  The solution was washed with a 
LiCl wash solution (100 mM Tris pH 7.5, 500 mM LiCl, 1% NP-40 and 1% sodium 
deoxycholate) at 4oC, and a final wash using 1X TE buffer.  Dynabeads were resuspended in an 
elution buffer (1% SDS and 0.1 M NaHCO3) and placed at 65°C to reverse crosslinks.  DNA was 
purified and a standard library preparation was performed prior to sequencing on an Illumina 
HiSeq 2000 sequencer.  Glucocorticoid receptor binding sites were identified using the MACS 
peak caller52. 
 
ChIP-seq analyses 
Reproducible glucocorticoid receptor ChIP-seq binding events were identified by a comparison 
of glucocorticoid receptor genome binding coordinates across replicate ChIP-seq experiments.  
Normalized read counts were assessed by compiling all reproducible binding events from control 
and CASP1 overexpressing cells (unique and common across both cells) and determining the 
number of reads, normalized to the total number of aligned reads per ChIP experiment, mapping 
to a 100-bp fragment of DNA centered on ChIP-seq binding site summits for all ChIP-seq 
replicate experiments.  The average normalized read counts for each cell was determined and 
used to determine the ratio of read counts between control and CASP1 overexpressing cells.  The 
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MEME program was used to identify enriched motifs at glucocorticoid receptor binding sites53.  
Normalized read count ratios are defined as the control divided by CASP1 overexpressing cell 
next-generation sequencing reads and a reproducible peak was defined as being identified by 
both replicate ChIP-seq experiments in each cell. 
 
Expression of CASP1 and NLRP3 in leukemia cells at the time of disease relapse versus at 
diagnosis 
Gene expression was assessed at diagnosis and relapse as previously described17. This dataset 
was MAS541 processed using the affy42 Bioconductor43 R-project package and then quantile 
normalized. A paired t-test was used for comparison of the matching diagnosis and relapse data. 
In a separate cohort of patients enrolled at St. Jude Children’s Research Hospital, dexamethasone 
LC50 was measured at time of diagnosis or relapse. 
 
Expression analysis of glucocorticoid sensitive and resistant xenograft ALLs 
Affmetrix U133Plus2 expression data of primary ALL cells expanded as xenografts in mice were 
downloaded from the Pediatric Preclinical Testing Program, and MAS5 processed using the 
affy42 Bioconductor43 R-project package.  Expression data was log2 transformed, and these ALL 
xenografts were categorized as either dexamethasone sensitive or dexamethasome resistant on 
the basis of their in vivo response to glucocorticoids26,27.  Those xenografts determined to exhibit 
partial (intermediate) or complete resistance in vivo were categorized as resistant, and those that 
were sensitive in vivo were categorized as sensitive26,27 . 
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Expression analysis of glucocorticoid-sensitive and resistant NCI60 ALL cell lines 
Expression data of the NCI60 ALL cell lines (Chiron Pharmaceuticals) were constant translated 
(add 0.1) to eliminate zero values prior to log2 transformation and combined with expression data 
from xenografts (see Supplementary Fig. 7) measured from RNA isolated at diagnosis.  
Additionally, expression data from NALM-6 cells were obtained and combined with this dataset.  
Data were median centered and scaled by dividing by the intrasample standard deviation, 
followed by quantile normalization.  NCI60 drug sensitivity measurements showed that all cells 
lines in the leukemia panel, except CCRF−CEM, were prednisolone resistant (accession number: 
NSC 19987, September 2014 release). 
 
  
37 
 
Methods-only references 
41. Hubbell, E., Liu, W.M. & Mei, R. Robust estimators for expression analysis. 
Bioinformatics 18, 1585-92 (2002). 
42. Gautier, L., Cope, L., Bolstad, B.M. & Irizarry, R.A. affy--analysis of Affymetrix 
GeneChip data at the probe level. Bioinformatics 20, 307-15 (2004). 
43. Gentleman, R.C. et al. Bioconductor: open software development for computational 
biology and bioinformatics. Genome Biol 5, R80 (2004). 
44. Cheok, M.H. et al. Treatment-specific changes in gene expression discriminate in vivo 
drug response in human leukemia cells. Nat Genet 34, 85-90 (2003). 
45. Yeoh, E.J. et al. Classification, subtype discovery, and prediction of outcome in pediatric 
acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-43 
(2002). 
46. Kuan, P.F., Wang, S., Zhou, X. & Chu, H. A statistical framework for Illumina DNA 
methylation arrays. Bioinformatics 26, 2849-55 (2010). 
47. Stouffer, S.A., Suchman, E.A., DeVinney, L.C., Star, S.A. & Williams Jr, R.M. The 
American soldier: adjustment during army life.(Studies in social psychology in World 
War II, Vol. 1.). (1949). 
48. Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. Nat 
Methods 8, 659-61 (2011). 
49. Boehm, J.S. et al. Integrative genomic approaches identify IKBKE as a breast cancer 
oncogene. Cell 129, 1065-79 (2007). 
50. Muzio, M., Salvesen, G.S. & Dixit, V.M. FLICE induced apoptosis in a cell-free system. 
Cleavage of caspase zymogens. J Biol Chem 272, 2952-6 (1997). 
51. Savic, D., Gertz, J., Jain, P., Cooper, G.M. & Myers, R.M. Mapping genome-wide 
transcription factor binding sites in frozen tissues. Epigenetics Chromatin 6, 30 (2013). 
52. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 9, R137 
(2008). 
53. Bailey, T.L., Williams, N., Misleh, C. & Li, W.W. MEME: discovering and analyzing 
DNA and protein sequence motifs. Nucleic Acids Res 34, W369-73 (2006). 
  
38 
 
Competing Interests 
Authors William E. Evans, Steven W. Paugh and Erik J. Bonten are named as co-inventors on a 
pending patent application that relates to the subject matter of the article, which was filed by St. 
Jude Children’s Research Hospital. 
 






